2005
Capítulo 8 Cardiopatía coronaria Síndromes coronarios agudos
Rutherford J, Yeung A, Reimold S, Willett D, Hiatt B, Lee D, Cigarroa J, Peshock R. Capítulo 8 Cardiopatía coronaria Síndromes coronarios agudos. 2005, 221-264. DOI: 10.1016/b978-84-8174-862-8.50008-9.Peer-Reviewed Original Research
2004
1100-62 Superior early platelet inhibition by 600mg clopidogrel loading in elective stenting
Gurbel P, Hiatt B, Gawaz M. 1100-62 Superior early platelet inhibition by 600mg clopidogrel loading in elective stenting. Journal Of The American College Of Cardiology 2004, 43: a65. DOI: 10.1016/s0735-1097(04)90272-0.Peer-Reviewed Original Research
2003
Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the tirofiban given in the emergency room before primary angioplasty (TIGER-PA) pilot trial
Lee D, Herity N, Hiatt B, Trial T. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the tirofiban given in the emergency room before primary angioplasty (TIGER-PA) pilot trial. ACC Current Journal Review 2003, 12: 67. DOI: 10.1016/s1062-1458(03)00308-8.Peer-Reviewed Original ResearchClopidogrel for Coronary Stenting
Gurbel P, Bliden K, Hiatt B, O’Connor C. Clopidogrel for Coronary Stenting. Circulation 2003, 107: 2908-2913. PMID: 12796140, DOI: 10.1161/01.cir.0000072771.11429.83.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine DiphosphateAgedAspirinBiomarkersClopidogrelCoronary Artery DiseaseDose-Response Relationship, DrugDrug ResistanceFemaleFlow CytometryGenetic VariationHumansMalePlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexP-SelectinStentsTiclopidineConceptsElective coronary stentingCoronary stentingPretreatment reactivityInterindividual variabilityAdverse ischemic eventsAlternative pharmacological strategiesPlatelet inhibitory responseDrug responseGlycoprotein IIb/IIIaIIb/IIIaIschemic eventsPlatelet inhibitionPlatelet reactivityStent thrombosisPharmacological strategiesBaseline aggregationCatheterization laboratoryInhibitory responsesClopidogrelL ADPPatientsP-selectinPlatelet aggregationStentingDaysThe early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition
Gurbel P, Bliden K, Hiatt B. The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. Journal Of Thrombosis And Haemostasis 2003, 1: 1319-1321. PMID: 12871340, DOI: 10.1046/j.1538-7836.2003.00184.x.Peer-Reviewed Original ResearchPlatelet activation after stenting with heparin-coated versus noncoated stents
Gurbel P, Bliden K, Hiatt B. Platelet activation after stenting with heparin-coated versus noncoated stents. Journal Of The American College Of Cardiology 2003, 41: 13. DOI: 10.1016/s0735-1097(03)80054-2.Peer-Reviewed Original Research
2002
Acute and long-term safety of pressurized myocardial transvenous delivery: confirmation by biochemical, echocardiographic, and histologic parameters
Herity N, Hiatt B, Fearon W, Suzuki T, McEneaney D, Berry G, Yeung A, Carter A, Fitzgerald P, Yock P. Acute and long-term safety of pressurized myocardial transvenous delivery: confirmation by biochemical, echocardiographic, and histologic parameters. Journal Of The American College Of Cardiology 2002, 39: 10. DOI: 10.1016/s0735-1097(02)80041-9.Peer-Reviewed Original ResearchHigh pressure, retrograde, coronary venous delivery of FGF-2 protein improves coronary blood flow in a porcine model of myocardial ischemia
Fearon W, Rezaee M, Hiatt B, Ikeno F, Bailey L, Suzuki T, Herity N, Fitzgerald P, Carter A, Yeung A, Yock P. High pressure, retrograde, coronary venous delivery of FGF-2 protein improves coronary blood flow in a porcine model of myocardial ischemia. Journal Of The American College Of Cardiology 2002, 39: 10. DOI: 10.1016/s0735-1097(02)80040-7.Peer-Reviewed Original Research
2001
The drug-eluting stent: is it the Holy Grail?
Hiatt B, Carter A, Yeung A. The drug-eluting stent: is it the Holy Grail? Reviews In Cardiovascular Medicine 2001, 2: 190-6. PMID: 12439368.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsIntimal hyperplasiaAdverse clinical eventsOnly effective treatmentMulticenter clinical trialSirolimus-coated stentsDrug-coated stentsBare metal stentsMinimal intimal hyperplasiaCoronary stentingRestenosis rateClinical eventsNegative remodelingClinical trialsComplex lesionsEffective treatmentStentsHyperplasiaRestenosisCardiologists